Eli Lilly Just Spent $6.3 Billion to Fix a Problem You Didn't Know It Had
Eli Lilly is paying up to $7.8 billion for Centessa Pharmaceuticals and its experimental sleep disorder drugs. It's the biggest signal yet that the GLP-1 king is building a second empire, and the orexin agonist race just got a lot more interesting.
The Pharma Giant That Couldn't Sleep
Eli Lilly has been on the most dominant run in pharma. Mounjaro and Zepbound turned it into the world's most valuable drug company. GLP-1 revenue is a fire hose of cash. So why is Lilly writing a $6.3 billion check for a company most people have never heard of?
Because Lilly has a blind spot. And it's in your bedroom.
On Tuesday, Lilly announced it would acquire Centessa Pharmaceuticals in a deal worth up to $7.8 billion, paying $38 per share in cash upfront plus contingent payments tied to FDA milestones. The target: sleep disorders, specifically narcolepsy and idiopathic hypersomnia (a condition where people sleep excessively and still feel exhausted). It's Lilly's biggest bet yet that its future isn't just about weight loss.
What Lilly Is Actually Buying
Centessa's crown jewel is cleminorexton, an oral drug that activates the orexin 2 receptor (OX2R) in the brain. Think of orexin as your brain's "stay awake" signal. In narcolepsy type 1, that signal is basically broken; patients lose the neurons that produce orexin. Current treatments manage symptoms. Cleminorexton aims to replace the missing signal directly.
The early data looks genuinely impressive. In a Phase 2a trial called CRYSTAL-1, a 1.5 mg dose delivered a greater than 20-minute increase in how long patients could stay awake versus placebo. For context, these are people who might fall asleep mid-sentence. That's a life-changing difference.
Cataplexy control was even more striking. Cataplexy is the sudden muscle weakness that narcolepsy patients experience, sometimes triggered by laughing or strong emotions. At the same dose, cleminorexton produced an 87% reduction in weekly cataplexy episodes compared to placebo. And the drug worked across narcolepsy types 1 and 2, plus idiopathic hypersomnia, which is unusual for this class.
Centessa also has two backup compounds (ORX142 and ORX489) in earlier development, giving Lilly a small portfolio rather than a single-asset gamble.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Follow the Money
The deal structure tells you a lot about how Lilly thinks about risk. The $38 per share in cash (roughly $6.3 billion) is the sure thing. That's what Lilly pays regardless. Then there's a contingent value right (CVR) worth up to $9 per share, split across three FDA approval milestones.
Those milestones break down like this: $2 per share if one of Centessa's drugs gets approved for narcolepsy type 2, $5 per share for an idiopathic hypersomnia approval, and $2 per share for any first FDA approval before January 1, 2030.
Notice the weighting. The biggest payout ($5) is tied to idiopathic hypersomnia, not narcolepsy. That tells you Lilly sees IH as the larger commercial prize, which makes sense: the IH market is smaller today but wildly underdiagnosed, and the condition has only one specifically approved drug (Xywav).
The deal represents a roughly 40% premium to Centessa's 30-day trading average. Wall Street approved. Lilly's stock rose about 2.9% on the news, which is the market's way of saying, "Yeah, this makes sense."
The Sleep Market Is Bigger Than You Think
Narcolepsy alone is projected to be a $4 to $5 billion global market in 2025-2026, growing at roughly 10% per year. Add idiopathic hypersomnia (estimated at $400 to $700 million in 2026 and climbing), and you're looking at a sizable combined opportunity.
But the real story is the gap between how many people have these conditions and how many are actually treated. Narcolepsy affects about 38 out of every 100,000 people in the U.S., yet diagnostic delays of several years are common. IH is even worse; prevalence estimates suggest the actual patient population could be several times larger than current diagnosis rates reflect.
Current treatments are imperfect, too. Oxybate therapies like Xyrem and Xywav require patients to wake up in the middle of the night for a second dose. Stimulants carry cardiovascular risks and abuse potential. Physicians consistently report that existing drugs leave room for improvement in both efficacy and safety. A drug that directly restores the brain's wakefulness signal, rather than just masking symptoms, could reshape the standard of care.
Lilly's Not Alone at the Party
There's a catch, though. Lilly isn't the only company that noticed orexin agonists could be massive.
Takeda is further ahead. Its orexin agonist, oveporexton, already has an NDA under Priority Review with a decision expected in Q3 2026. Two Phase 3 trials hit all primary and secondary endpoints. If approved, oveporexton would be the first OX2R agonist on the market, potentially before Centessa's drugs even finish pivotal trials.
Alkermes is also in the race with alixorexton, which posted positive Phase 2 data in both narcolepsy type 1 and type 2. Jazz Pharmaceuticals tried to play but had to pause its candidate, JZP441, after Phase 1 safety concerns.
So Lilly is entering a competitive field, not an empty one. The bull case is that the market is big enough for multiple winners (analysts at Stifel have argued exactly this) and that cleminorexton's data across all three sleep conditions could carve out a differentiated position. The bear case: Lilly just paid $6.3 billion for a Phase 2 asset in a race where Takeda is already at the finish line.
The Bigger Picture: Lilly's GLP-1 ATM Strategy
Zoom out, and Centessa fits a clear pattern. Lilly is systematically converting GLP-1 profits into diversification. In the past year alone, the company has acquired SiteOne Therapeutics (pain, up to $1 billion), 4E Therapeutics (pain), Ventyx Biosciences (immunology, roughly $1.2 billion), and vaccine companies totaling nearly $4 billion.
Neuroscience is emerging as one of the biggest bets. With Kisunla (donanemab) in Alzheimer's, multiple pain acquisitions, and now a sleep franchise via Centessa, Lilly is building a CNS portfolio that could eventually stand on its own alongside the metabolic business.
The logic is simple: GLP-1 drugs won't dominate forever. Patents expire. Competitors catch up. Lilly is using the cash machine while it's running to build the next one.
Whether sleep disorders become Lilly's next multi-billion-dollar franchise depends on Phase 3 data that doesn't exist yet. But at $38 per share, Lilly is buying the option. The CVR structure means Centessa shareholders share in the upside if things work out, and Lilly limits its downside if they don't. It's a bet, but a carefully structured one, on a market that most of pharma has been sleeping on.
Deals & M&A5 min read
Servier Just Dropped $2.65 Billion on a Drug That Doesn't Exist Yet
French pharma giant Servier is paying up to $2.65 billion for a muscular dystrophy drug that hasn't even finished its pivotal trial. The bet: that protecting fragile muscles from damage, rather than fixing the underlying genetic defect, could become the backbone of treatment.
